Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher R Gibson

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 23, 2003
Bioactivation of the 3-amino-6-chloropyrazinone ring in a thrombin inhibitor leads to novel dihydro-imidazole and imidazolidine derivatives: structures and mechanism using 13C-labels, mass spectrometry, and NMRRaju Subramanian, Charles C Lin, Jonathan Z Ho, et al.
Mabs|January 16, 2010
IgG2m4, an engineered antibody isotype with reduced Fc functionZhiqiang An, Gail Forrest, Renee Moore, et al.
Journal of Clinical Pharmacology|June 5, 2014
Prednisone has no effect on the pharmacokinetics of CYP3A4 metabolized drugs - midazolam and odanacatibEugene E Marcantonio, Jeanine Ballard, Christopher R Gibson, et al.
Bioorganic & Medicinal Chemistry Letters|May 3, 2016
Synthesis and optimization of N-heterocyclic pyridinones as catechol-O-methyltransferase (COMT) inhibitorsZhijian Zhao, Scott T Harrison, Jeffrey W Schubert, et al.
Journal of Pharmaceutical Sciences|April 12, 2011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approachRagini Vuppugalla, Punit Marathe, Handan He, et al.
Journal of Pharmaceutical Sciences|April 28, 2011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasetsPatrick Poulin, Hannah M Jones, Rhys Do Jones, et al.
Journal of Pharmaceutical Sciences|May 5, 2011
PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approachPatrick Poulin, Rhys D O Jones, Hannah M Jones, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 19, 2005
Induction of CYP1A in the beagle dog by an inhibitor of kinase insert domain-containing receptor: differential effects in vitro and in vivo on mRNA and functional activityChristopher R Gibson, Charles Lin, Rominder Singh, et al.
Journal of Pharmaceutical Sciences|May 5, 2011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearanceBarbara J Ring, Jenny Y Chien, Kimberly K Adkison, et al.
Journal of Pharmaceutical Sciences|April 1, 2011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distributionRhys Do Jones, Hannah M Jones, Malcolm Rowland, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 23, 2003
Bioactivation of the 3-amino-6-chloropyrazinone ring in a thrombin inhibitor leads to novel dihydro-imidazole and imidazolidine derivatives: structures and mechanism using 13C-labels, mass spectrometry, and NMRRaju Subramanian, Charles C Lin, Jonathan Z Ho, et al.
Mabs|January 16, 2010
IgG2m4, an engineered antibody isotype with reduced Fc functionZhiqiang An, Gail Forrest, Renee Moore, et al.
Journal of Clinical Pharmacology|June 5, 2014
Prednisone has no effect on the pharmacokinetics of CYP3A4 metabolized drugs - midazolam and odanacatibEugene E Marcantonio, Jeanine Ballard, Christopher R Gibson, et al.
Bioorganic & Medicinal Chemistry Letters|May 3, 2016
Synthesis and optimization of N-heterocyclic pyridinones as catechol-O-methyltransferase (COMT) inhibitorsZhijian Zhao, Scott T Harrison, Jeffrey W Schubert, et al.
Journal of Pharmaceutical Sciences|April 12, 2011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approachRagini Vuppugalla, Punit Marathe, Handan He, et al.
Journal of Pharmaceutical Sciences|April 28, 2011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasetsPatrick Poulin, Hannah M Jones, Rhys Do Jones, et al.
Journal of Pharmaceutical Sciences|May 5, 2011
PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approachPatrick Poulin, Rhys D O Jones, Hannah M Jones, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 19, 2005
Induction of CYP1A in the beagle dog by an inhibitor of kinase insert domain-containing receptor: differential effects in vitro and in vivo on mRNA and functional activityChristopher R Gibson, Charles Lin, Rominder Singh, et al.
Journal of Pharmaceutical Sciences|May 5, 2011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearanceBarbara J Ring, Jenny Y Chien, Kimberly K Adkison, et al.
Journal of Pharmaceutical Sciences|April 1, 2011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distributionRhys Do Jones, Hannah M Jones, Malcolm Rowland, et al.
Pageof 3